3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Thrombocythemia, Essential
1
Myeloproliferative Disorders
1
Interventions
ruxolitinib
7
fludarabine phosphate
3
bomedemstat
3
Whole-Body Irradiation
3
Tacrolimus
3
Specimen Handling
3
Mycophenolic Acid
3
Cyclophosphamide
3
Biopsy
3
fludarabine
2
Stem Cell Transplantation
2
Peripheral Blood Stem Cell Transplantation
2
Methotrexate
2
Melphalan
2
Injections
2
Busulfan
2
venetoclax
1
veliparib
1
piperine
1
pevonedistat
1
iadademstat
1
fedratinib
1
demethoxycurcumin
1
decitabine and cedazuridine drug combination
1
anagrelide
1
X-Rays
1
Valganciclovir
1
Transplantation
1
Topotecan
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thrombocythemia, Essential
×
anagrelide
×
1 year
×
Clear all
NCT04285086
2025-08-13
SURPASS ET
PharmaEssentia
Phase 3
Active not recruiting
174 enrolled